Overall, the glioblastoma patients experiencing cancer progression following anti-PD1 therapy displayed distinctive immune signatures, marked by deficiencies in macrophage, monocyte, and T follicular helper responses, impaired antigen presentation, skewed Tregs response, and heightened expression of immunosuppressive molecules (TGFB, IL2RA, and CD276). This evidence concerns the gene PDCD1 and cancer.